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Abstract With more than 6,000 new pediatric patients with
treatment-resistant nephrotic syndrome in the US each year
alone, the unmet need for novel, podocyte-specific therapies is
substantial. Recently, the established therapeutic benefit of
angiotensin-converting enzyme (ACE) inhibitors and angioten-
sin receptor blockers (ARB) was used as a starting point to gain
insight into the pathomechanism of primary podocytopathies. A
calcium (Ca2+)-mediated pathway has been identified that con-
nects the angiotensin type 1 receptor (AT1R) to podocyte cyto-
skeletal dynamics, essential for a functioning glomerular filtra-
tion barrier. This discovery provided an important missing piece
in our understanding of the pathomechanism of filter barrier
damage, revealing Ca2+ signaling as critical for podocyte health
and disease. The identification of the two Ca2+ permeant chan-
nels TRPC5 and TRPC6 as mediators of this pathway not only
bolstered the importance of podocyte cytoskeleton dynamics but
also revealed promising drug targets for treatment-resistant ne-
phrotic syndrome. This reviewwill focus on this novel signaling
pathway in primary podocytopathies and its implications for
next-generation therapies for glomerular disease.
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Case report
A 16-year-old boy who presented with nephrotic syndrome
since the age of 7, with an initial biopsy showing minimal
change disease (MCD), and with a subsequent biopsy show-
ing primary FSGS (focal segmental glomerulosclerosis) at age
9, presented with relapsing steroid-resistant nephrotic syn-
drome. The patient had preserved renal function with an av-
erage serum creatinine 0.5 mg/dl. His medications included
lisinopril 10 mg daily, simvastatin 40 mg daily, and furose-
mide as needed, titrated to symptoms. Cyclosporine A, cyto-
toxic therapy with cyclophosphamide, mycophenolate mofe-
til, and rituximab had been added to steroids at different times
during his adolescent years, without success in achieving re-
mission. At age 16, while in partial remission on high-dose
oral steroids, and during a subsequent attempt to slowly taper
the steroids, he experienced recurrence of proteinuria with a
urinary protein/creatinine ratio (UPC) of 12. Multiple attempts
to achieve remission with high-dose steroids were unsuccess-
ful. A few weeks later, he was admitted to the hospital with
anasarca that required intravenous diuretics. A repeat kidney
biopsy confirmed the diagnosis of primary podocytopathy or
FSGS. What further therapeutic interventions may be avail-
able to this patient with steroid-resistant nephrotic syndrome?
Introduction
A podocentric view of glomerular disease
One of the main tasks of the kidney is to deplete low molec-
ular weight molecules from the plasma, while larger, vital
proteins such as albumin are retained in the bloodstream [1].
The glomerulus thereby constitutes the body’s filtration barri-
er and is, in this context, viewed as the central functional entity
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of the kidney [2]. A well-coordinated interplay of mesangial
cells, parietal cells, endothelial cells, and podocytes is required
to maintain the microscopically and macroscopically highly
organized structure of the glomerulus [3]. Disruption of this
system leads to glomerular disease, a large group of kidney
diseases, characterized by proteinuria [4].
Based on the underlying diseasemechanism, wewould like
to reinforce a podocentric classification that distinguishes pri-
mary and secondary podocytopathies. While secondary
podocytopathies are the consequence of well-defined inflam-
matory responses in a variety of immune-mediated glomerular
diseases such as ANCA vasculitis, lupus nephritis, or other
immune complex glomerulonephritides, where the podocyte
may be Bcollateral damage^ due to primary endothelial and
immune complex-mediated injury, primary podocytopathies
are caused, by definition, by podocyte-specific injury.
Histologically, primary podocytopathies are a heterogeneous
group of kidney diseases with a great variety of anatomical
features. These range from profound structural changes in the
podocyte cytoskeleton only detectable at the electron micro-
scopic level (as in foot process effacement in the euphemisti-
cally named Bminimal change^ disease (MCD)) all the way to
profound light microscopically detectable focal sclerosis (as in
FSGS) and/or completely collapsed glomeruli (as in collaps-
ing glomerulonephritis) [3]. This review will mostly be con-
cerned with primary podocytopathies.
The filtration barrier is composed of the fenestrated endo-
thelium of the glomerular vessels, the glomerular basement
membrane (GBM), and the interdigitating podocyte foot pro-
cesses (FPs). Podocyte structures called slit diaphragms (SD)
function like modified adherens junctions connecting neigh-
boring FPs [5]. Through human genetic studies [3], a set of
well-characterized proteins (such as nephrin, podocin, and
others) have been identified in the SD as critical for
podocyte–podocyte adhesion as well as signaling from the
SD to the actin cytoskeleton [3]. Podocyte cell bodies float
in the urinary space inside Bowman’s capsule, fixed only
through their FPs to neighboring podocytes and through focal
adhesions to the GBM [6]. Upon podocyte stress or injury,
podocytes undergo a set of canonical structural changes, in-
cluding foot process effacement (FPE) [6]. It has been pro-
posed that FPE is a compensatory, adaptive mechanism for
podocytes to avoid detachment [6]. Failure to maintain attach-
ment appears to trigger mechanisms that lead to podocyte
death, the hallmark of advanced glomerular disease [3].
Based on the essential role of the podocyte slit diaphragms
as part of the renal filtration barrier [1] and podocyte cytoskel-
eton rearrangements as early compensatory responses to
podocyte injury [6], podocytes have been rightly placed at
the center of ongoing investigations into the pathomechanism
of glomerular disease [3, 4].
Understanding the importance of the podocyte cytoskele-
ton for a functioning renal filter barrier poses a fundamental
question: What is the underlying mechanism of cytoskeletal
rearrangements in podocytes? Starting from the established
benefit of angiotensin-converting enzyme (ACE) inhibitors
and angiotensin receptor blockers (ARB) as our first-line,
standard-of-care therapy for glomerular disease [7], and ask-
ing what mediates their anti-proteinuric, podocyte-specific ef-
fect, has revealed an interesting answer: a Ca2+-mediated path-
way connects the angiotensin type 1 receptor (AT1R) to
podocyte cytoskeletal dynamics. This pathway indeed provid-
ed an explanation for an important missing piece in our un-
derstanding of the pathomechanism of filter barrier damage,
revealing Ca2+, a central player of the intracellular signaling
apparatus in any cell type, as critical for podocyte health and
disease. This review will focus on this novel signaling path-
way and its implications for next generation therapies for glo-
merular disease.
Calcium signaling
Ca2+ is a vital second messenger in virtually every cell type
[8]. It orchestrates a great variety of different cellular functions
such as muscle contraction [9], fertilization [10], neurotrans-
mitter release [11], cytoskeleton dynamics [12] and apoptosis
[13, 14]. Ca2+ signaling relies on a low intracellular Ca2+
resting concentration [Ca2+]i (0.1 μM), roughly four orders
of magnitude below the extracellular Ca2+ concentration
[Ca2+]e (2 mM). A Ca
2+ signal is induced by an increase of
the [Ca2+]i, whereby the major sources of Ca
2+ are the extra-
cellular space and intracellular Ca2+ stores such as the endo-
plasmic reticulum (ER) and the mitochondria [15].
Specialized ion channels, pumps, and cytosolic Ca2+ buffers
constitute the cellular Ca2+ regulatory apparatus. Their well-
coordinated interplay allows both the induction of intracellular
Ca2+ signals (ON mechanisms) and the relaxation of the sys-
tem towards its vital low resting [Ca2+]i (OFF mechanisms)
[16]. ON mechanisms are usually mediated by ion channels
which, upon opening, allow Ca2+ to diffuse along its concen-
tration gradient into the cytosol. Common examples include
voltage-dependent Ca2+ channels (VDCCs) and intracellular
ligand-gated Ca2+ release channels, such as the inositol 1,4,5-
trisphosphate receptor (IP3R) or the ryanodine receptor
(RYR), predominantly located on the ER membrane [15,
16]. OFF mechanisms, by contrast, extrude Ca2+ from the
cytosol, thus pumping Ca2+ against its concentration gradient
either into the extracellular space or into intracellular Ca2+
stores. Important examples are the sarco/endoplasmic reticu-
lum Ca2+-ATPase (SERCA) and the plasma membrane Na+/
Ca2+-exchanger (NCX) [15, 16]. Upon elevated [Ca2+]i, Ca
2+
binds to highly conserved Ca2+ binding domains, such as EF-
hand domains [17]. By introducing its two-fold positive
charge, Ca2+ induces a conformational change in these pro-
teins, which can lead to an alteration of their function. Ca2+-
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sensing proteins are functionally highly diverse and range
from transcription factors and phosphatases [8] to elements
of the cytoskeleton [12] and proteins of the contractile appa-
ratus in muscle cells [18]. A prolonged increase in [Ca2+]i
induces cell death [13, 14] and thus Ca2+ signals are required
to be temporally limited. Furthermore, to be able to mediate
the great variety of Ca2+-dependent cellular functions, Ca2+
signals are not necessarily binary signals, but can also encode
information in a frequency-dependent manner (for example,
as Ca2+ oscillations) [18]. Spatial heterogeneity is another
important aspect to understand the high specificity of Ca2+
signals. Instead of looking at the cell as a single homogeneous
system, it is necessary to identify so-called Ca2+ microdo-
mains, sub-femto liter domains that accumulate important
Ca2+ signaling elements. Such microdomains can be
predetermined by structural features of the cell, such as den-
dritic spines in neurons [19] or FPs in podocytes [20], or their
spatial extent can be limited by diffusion and the cytosolic
Ca2+ buffering capacity. Acknowledgment of the importance
of Ca2+ microdomains to our understanding of Ca2+ signaling
in general is constantly increasing [21], which is reflected in a
growing number of theoretical studies investigating the math-
ematical foundations of the complex non-linear dynamics of
Ca2+ microdomains [22–25].
TRPC channels and calcium signaling in podocytes
Transient receptor potential (TRP) channels are a heteroge-
neous group of non-selective cationic channels, containing
28 human homologs, subdivided into seven subfamilies [26,
27]. Two members of the canonical TRP (TRPC) channel
subfamily have been identified to play a major role in the
Ca2+ homeostasis of podocytes, namely TRPC6 and TRPC5
[28] (Fig. 1). Human genetics has revealed TRPC6 as a vital
component of the slit diaphragm [29], and further investiga-
tion into gain-of-function TRPC6 mutations ultimately led to
the identification of TRPC5 as a critical inducible mediator of
Ca2+-induced cytoskeletal remodeling in podocytes [28], an
important event at the onset of all podocytopathies [30, 31].
Angiotensin II-mediated Ca2+ signals
The beneficial therapeutic effects of renin–angiotensin–aldo-
sterone system (RAAS) inhibition in primary podocytopathies
are well established [32]. However, molecular insights into the
underlying mechanisms were lacking until the AT1R was
identified as the upstream receptor signaling to both TRPC5
and TRPC6 in podocytes [28]. The Gq subunit of the G-
protein-coupled AT1R activates phospholipase C (PLC),
which in turn controls TRPC5 /TRPC6 gating. While the de-
tailed mechanisms for differential and specific activation of
each channel have not yet been fully elucidated, the activation
of both channels leads to Ca2+ influx into podocytes, with
distinct cellular responses [28].
Tian et al. showed that while TRPC6 activates RhoA, in-
ducing a stationary, homeostatic podocyte phenotype, TRPC5
activates Rac1 inducing a disease-associated motile pheno-
type: in other words, triggering a cellular program that centers
on Rac1 tomediate maladaptive cytoskeletal remodeling lead-
ing to FPE [28, 30]. Indeed, prior to the work revealing
TRPC5/Rac1 and TRPC6/RhoA coupling, the small Rho
GTPases (RhoA, Rac1, and Cdc42) had been associated with
different aspects of cell motility and cytoskeleton dynamics in
TRPC6
Homeostatic
TRPC5
Inducible
Rho A Synaptopodin
Intact Cytoskeleton
Filter Barrier 
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Fig. 1 Simplified schematic presentation of our current understanding of
TRPC channels in podocytes in health and disease. TRPC6 has a
homeostatic function, maintaining a functioning podocyte cytoskeleton
through RhoA activation and thus an intact filter barrier. Increased
activity (e.g., gain-of-function mutations) disrupts cytosolic Ca2+ homeo-
stasis and is known to cause focal segmental glomerulosclerosis (FSGS). In
contrast, TRPC5 is inducible and activates Rac1, which has been shown to
cause cytoskeletal collapse and consecutive filter barrier damage
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podocytes [31], but they had not been linked to the TRPC
channels or to Ca2+ signaling.
However, how can individual TRPC channels mediate dis-
tinct cellular events? A unifying explanation can be found in
the existence of Ca2+ microdomains in podocytes, to which
each TRPC channel introduces small amounts of Ca2+, locally
increasing [Ca2+]i, sufficient to activate a localized effector
[28]. Thus, both TRPC5 and TRPC6 are essential for a func-
tioning podocyte cytoskeleton: gene silencing of TRPC6 in-
duces the activation of Rac1, the loss of stress fibers and
increased podocyte motility, in summary a motile phenotype.
Constitutive activation of RhoA rescues the phenotype [28].
Interestingly, similar to gain-of-function mutations in humans,
overexpression of TRPC6 in podocytes in vitro also leads to
loss of stress fibers in podocytes [33] and proteinuria in mice
[34], indicating the necessity of a well-balanced TRPC6 ac-
tivity to maintain a healthy podocyte cytoskeleton (Fig. 1).
Conversely, gene silencing of TRPC5 induces stress fiber for-
mation and RhoA activation and decreases podocyte motility,
and thus leads to a stationary phenotype. In this case, consti-
tutive activation of Rac1 rescues the phenotype [28]. In sum-
mary, these findings suggested that instead of the activity of
one particular pathway in podocytes, it is the balanced activity
of both TRPC6/RhoA and TRPC5/Rac1 that is critically im-
portant. Subsequent work in vivo corroborated these findings
and further showed that, in the setting of early proteinuric
disease, TRPC5 is induced to activate Rac1 leading to FPE.
Most importantly, this could be blocked by a small molecule
inhibitor, ML204, in a dose-dependent fashion. This work
revealed a new, ion channel-targeted approach to anti-
proteinuric therapy [30].
Calcineurin signaling
The Ca2+-dependent phosphatase calcineurin is typically
known for activating the transcription factor nuclear factor
of activated T-cell (NFAT) in T-cells, upregulating interleukin
2 (IL-2), and thus inducing the T-cell response [35]. However,
calcineurin has also been shown to have a distinct role in
podocytes. Calcineurin activation leads to cathepsin L-
mediated cleavage of the vital, actin-associated protein
synaptopodin [36], which plays an essential role in podocyte
cytoskeletal homeostasis [37]. Activation of calcineurin in-
duces synaptopodin cleavage and proteinuria, while the cal-
cineurin inhibitor cyclosporine A (CsA) prevents it [38]. This
finding challenged the idea that the treatment of proteinuric
kidney diseases with CsA is based on immunomodulation,
and emphasized instead the importance of an intact
podocyte cytoskeleton for the glomerular filtration barrier
[3], revealing the podocyte as the therapeutic target of
choice for glomerular diseases.
The fact that FSGS-causing TRPC6 gain-of-function mu-
tations activate calcineurin-NFAT-dependent gene transcrip-
tion [39] further points towards an important role of TRPC
channels and calcineurin signaling in podocytes. In cardiac
hypertrophy, the calcineurin-NFAT pathway induces the up-
regulation of TRPC6 transcription [40] and, as just recently
proposed, a similar mechanism appears to exist in podocytes
[41]. Perhaps this mechanism constitutes an auto-regulatory
positive feedback loop, eventually increasing the presence of
TRPC6 channel density on the plasma membrane. Further
investigations need to be directed towards the understanding
of this mechanism to elucidate the full scope of TRPC
channel-induced podocytopathies.
Discussion
How do the experimental findings summarized here translate
into clinical medicine? One way to evaluate the significance
of these insights is to look at the consequences of mutations in
key molecules of the proposed signaling pathway. Mutations
of TRP channels have been associated with a number of dif-
ferent diseases. Such TRP channelopathies include night
blindness (TRPM1) [42], progressive familial heart block type
I (TRPM4) [43], hypomagnesemia with secondary hypocal-
cemia (TRPM6) [44], and autosomal dominant polycystic kid-
ney disease (TRPP2) [45], to name a few. In 2005, mutations
in TRPC6 were identified in several forms of hereditary FSGS
[29, 46].
At that time, proteinuric kidney disease was primarily as-
sociated with rearrangements in the cytoskeletal structure of
podocytes, thus the identification of a Ca2+ channel causing
FSGS init ially suggested the potential for a new
pathomechanism [46]. However, by connecting TRPC6 acti-
vation to podocyte cytoskeletal remodeling, we in fact gained
further evidence to bolster the view of impaired cytoskeletal
dynamics as the central pathomechanism of early proteinuric
kidney disease [28]. Just recently, the important role of
TRPC6 in this context was highlighted in a mouse model with
constitutively active Gqα subunits in podocytes [41]. The
consequent increased activation and upregulation of an ion
channel identified as TRPC6 was shown to induce albumin-
uria and FSGS, as well as a decrease in the number of glomer-
ular podocytes [41]. This study did not investigate a role for
TRPC5 in this mouse model, but despite the lack of these
specific data, the fact that orthogonal approaches continue to
implicate TRPC channels in the emergence of FSGS further
bolsters the idea that TRPC channels and Ca2+-mediated path-
ways may be excellent therapeutic targets for a disease that
currently lacks effective treatment options.
Drugs targeting ion channels are in widespread clinical use:
common representatives are verapamil (voltage-gated L-type
Ca2+ channel blocker), lidocaine (voltage-gated Na+ channel
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blocker) and diazepam (GABAA, ligand-gated Cl− channe6l)
[47]. Historically, early attempts at drug targeting of ion chan-
nels had limited success due to lack of specificity and signif-
icant off-target effects, which limited their applicability [48].
However, in the last decades, great progress has been made in
our understanding of ion channel structures and function, and
consequently we have developed drugs with greater specific-
ity and fewer off-target effects [47]. Modern techniques for
systematic high-throughput drug screening have also made
the identification of new compounds more feasible.
Given the orthogonal convergence of human genetics
(TRPC6), the cell biology of the actin cytoskeleton
(RhoGTPases) and our new knowledge of Ca2+ physiology
in podocytes (TRPC5 and TRPC6), we may now be poised to
uncover new treatment options for primary podocytopathies
based on the modulation of TRPC5 and TRPC6 channel
activity.
A first promising step in this direction was the identifica-
tion of ML204, a small molecule inhibitor of TRPC4/5 chan-
nels [49]. Since TRPC4 is not expressed in podocytes [30],
whereas TRPC5 has been detected at the single channel level
by electrophysiology studies in podocytes [28], the effect of
ML204 on podocyte TRPC5 became the focus of investiga-
tion. Combining experiments in TRPC5 knockout mice,
ex vivo physiology in isolated glomeruli, in vitro real-time
live imaging of the podocyte cytoskeleton, the lipopolysac-
charide (LPS) and the protamine sulfate (PS) models of pri-
mary podocytopathies in vivo, TRPC5 was found to be the
upstream regulator of LPS-induced albuminuria and PS-
induced filter barrier disruption [30]. Based on these data,
disease-induced upregulation of TRPC5 with a consequent
disruption of the balance between the RhoA and Rac1 path-
ways in favor of Rac1, suggests that a TRPC5-specific inhib-
itor must be able to restore physiologic (TRPC6 and RhoA-
mediated) Ca2+ homeostasis in podocytes. Indeed, the small
molecule inhibitor ML204 was not only shown to be an effec-
tive pore blocker of TRPC5-mediated Ca2+ transients in
podocytes, but it was also shown to rescue podocytes from
disease-associated cytoskeletal remodeling. This effect was
further validated with Ca2+ imaging in isolated glomeruli, em-
phasizing the physiological relevance of the in vitro model in
podocytes [30]. These data, which await validation in other
models of progressive proteinuric kidney disease, emphasize
the central role of TRPC5 in primary podocytopathies and
raise hope that targeting TRPC5 may indeed ultimately offer
a novel treatment option for glomerular diseases caused by the
disruption of the podocyte cytoskeleton.
The finding that gain-of-function mutations in TRPC6
cause familial FSGS [46] has also provided an excellent ratio-
nale for significant effort in identifying potent TRPC6 inhib-
itors as a therapeutic approach to podocytopathies. A number
of inhibitors have indeed been developed, some with a favor-
able specificity profile for TRPC6 over its close homologs
TRPC3 and TRPC7 [50]. However, careful consideration of
an important nuance about TRPC6 may, and probably should,
somewhat diminish enthusiasm for drugs targeting TRPC6:
careful cell biological and physiological analysis by a number
of groups has shown that TRPC6 plays an important homeo-
static role in podocytes, as it is essentially important for main-
tenance of RhoA signaling and cytoskeletal integrity [28, 51].
In our understanding, blocking or abrogating an essential ho-
meostatic mechanism in podocytes by blocking homeostatic
TRPC6 activity is likely to lead to the opposite of the intended
therapeutic effect: we expect it to actually cause or worsen
FPE and proteinuria. By this scenario, it is only in the event
of gain-of-function mutations in TRPC6 (or perhaps signifi-
cantly enhanced channel activity or upregulation) where a
TRPC6 blocker may be effective to dampen or block the in-
jurious excess activity (which translates into excess Ca2+-me-
diated toxicity and cell death [52–55]). Therefore, this may be
a case in which a simple, initial glance at the genetics might
seemingly point in the direction of blocking TRPC6, but a
nuanced understanding of the physiology and cell biology
may suggest that alternative strategies should be sought, ones
that only attack inducible, and not homeostatic, Ca2+ influx.
Identification of the Ca2+-regulated phosphatase calcine-
urin as an important link between TRPC/Ca2+ signaling and
cytoskeletal dynamics in podocytes [20, 28] introduced a new
view on the mechanism of action of cyclosporin A (CsA) in
FSGS and other glomerular diseases. Instead of acting through
its classical immunologic effect on NFAT signaling in T-cells,
it appears to inhibit calcineurin in a podocyte-specific manner
to protect the podocyte homeostatic structural protein
synaptopodin from dephosphorylation and ultimate degrada-
tion [38]. Considering the unfavorable spectrum of kidney-
specific side effects of long-term use of CsA, including
hyalinosis and interstitial fibrosis, direct targeting of
podocyte-specific calcineurin substrates such as synaptopodin
may offer a good alternative strategy for the development of
novel anti-proteinuric drugs with podocyte-specific CsA-like
effects [38]. Specifically, a synaptopodin protective agent may
in fact be an excellent therapeutic strategy.
The emerging importance of the essential role of an intact
podocyte cytoskeleton for a functioning filtration barrier has
been further bolstered by the identification of B7-1 (CD80),
as yet another potentially druggable component of the regula-
tory apparatus of the podocyte cytoskeleton. B7-1 was shown
to be upregulated upon podocyte injury [56], thus preventing
podocyte beta 1 integrin activation, and eventually leading to
cytoskeletal remodeling in podocytes in vitro and in vivo [56].
The biologic abatacept has traditionally been used for the treat-
ment of rheumatoid arthritis (RA) [57], where it acts as a T-cell
inhibitor by binding to CD80 (B7-1) and CD86, thus blocking
the costimulatory receptor CD28 [58]. Understanding of the
role of B7-1 as a T-cell-independent, podocyte-specific cyto-
skeleton regulator motivated a proof of concept study, in which
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abatacept was used as a treatment in five patients with
treatment-resistant nephrotic range proteinuria [56]. Abatacept
induced remission in all five patients and thereby impressively
confirmed the central role of the podocyte cytoskeleton in glo-
merular disease in general and the pathophysiological signifi-
cance of B7-1 in particular.
Conclusions
The hallmark of primary podocytopathies is proteinuria, a
direct consequence of filter barrier damage. Functionally,
podocytes are critical for maintaining an intact filtration bar-
rier [3]. Importantly, podocytes are terminally differentiated
cells, quite similar to neurons, and therefore their capacity
for regeneration is limited. Podocytes have developed potent
Badaptive^ mechanisms to cope with acute and chronic stress
and injury. Also similar to neurons, podocytes have exquisite
mechanisms for the tight control of Ca2+ homeostasis, because
the consequence of excess Ca2+ is cytoskeletal collapse [30,
52–55] without the possibility of a suitable replacement. In
this scenario, FPE may be seen as an initial (futile) attempt to
maintain a (filtration) barrier in the face of injury. Clinically,
this manifests as proteinuria, and precedes the presence of
histological sclerotic lesions, which are the result of podocyte
death and maladaptive proliferation of parietal epithelial cells
on the denuded GBM [59].
The identification of TRPC5 and TRPC6 as upstream regula-
tors of Ca2+-mediated cytoskeletal rearrangements in podocytes,
and the notion of maintaining a proper balance between homeo-
static TRPC6/RhoAversus inducible TRPC5/Rac1 activity con-
stitutes a novel paradigm for understanding filter barrier damage
in proteinuric diseases. Together with the development of im-
proved TRPC channel inhibitors, these findings constitute a
new approach to the unmet need of effective treatment options
for primary podocytopathies such as MCD, FSGS, and diabetic
kidney disease, as well as other acquired proteinuric kidney dis-
eases. Furthermore, new drugs interacting with downstream tar-
gets of calcineurin, most importantly synaptopodin, could con-
stitute a treatment option that is, due to an optimized side effect
spectrum, more attractive than the currently used CsA (Fig. 2).
Patients with initial MCD diagnoses, resistant to steroid
treatment, with subsequent biopsies showing FSGS, as de-
scribed in the case report at the beginning of this review,
appear frequently in the renal clinic. Following the here-
proposed mechanistic understanding of the pathogenesis of
primary podocytopathies, the seemingly distinct entities we
call MCD and FSGS may not necessarily be two different
diseases, but rather the transition from an initial state of a
collapsed cytoskeleton (MCD) to a decompensated state of
permanent podocyte loss and replacement with scar (FSGS).
This new, molecularly-defined understanding of the mecha-
nisms underlying primary podocytopathies also brings into
crisper focus the therapeutic potential of targeting the
podocyte cytoskeleton.
With more than 6,000 new pediatric patients suffering from
treatment-resistant nephrotic syndrome in the US each year alone
[60], the unmet needs of patients with treatment-resistant ne-
phrotic syndrome is substantial, and calls for novel, podocyte-
specific therapies. While first results are promising, further stud-
ies are necessary to advance towards a futurewhen clinicianswill
have at their disposal an array of molecular targeted, precision
medicine strategies for primary podocytopathies.
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